Thurston, Springer, Miller, Herd & Titak, Inc. Novo Cure LTD Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $558 Million
- Q1 2025
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Novo Cure LTD stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 517 shares of NVCR stock, worth $9,378. This represents 0.0% of its overall portfolio holdings.
Number of Shares
517
Previous 527
1.9%
Holding current value
$9,378
Previous $15,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding NVCR
# of Institutions
292Shares Held
75.9MCall Options Held
1.77MPut Options Held
538K-
Black Rock Inc. New York, NY12.1MShares$220 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$214 Million0.01% of portfolio
-
Capital International Investors Los Angeles, CA8.87MShares$161 Million0.05% of portfolio
-
Capital World Investors Los Angeles, CA4.82MShares$87.4 Million0.02% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.74MShares$49.7 Million5.68% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $1.9B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...